Search

Displaying results 1161 - 1170 of 10000 in total
  1. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

    Synonyms: Sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2- yl}oxy)methyl hydrogen phosphate - 2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)
  2. Drug

    Bexicaserin

    go.drugbank.com/drugs/DB18885
    Investigational

    Bexicaserin is under investigation in clinical trial NCT05626634 (Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy).

    Synonyms: (7R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro[1,4]diazepino[6,7,1-hi]indole-8-carboxamide
  3. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    Anacaulase (anacaulase-bcdb) is a mixture of proteolytic enzymes extracted from the stems of pineapple plants (_Ananas comosus_ [L.] Merr.). … It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  4. Drug

    Sulindac

    go.drugbank.com/drugs/DB00605
    ApprovedInvestigational

    Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. … Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes.

    Categories: Non COX-2 selective NSAIDSSynonyms: (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid, cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid
  5. Pathway

    Imatinib Inhibition of BCR-ABL

    smpdb.ca/view/SMP0031694
    Drug action

    Imatinib is a tyrosine kinase inhibitor used to treat cancers such as chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these ce...

    Drugs: Imatinib
    Enzymes: S-phase kinase-associated protein 2
  6. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most … It is an attractive target for immunotherapy.

    Synonyms: ING-1
  7. Indication

    Insomnia

    go.drugbank.com/conditions/DBCOND0017531
    Drugs: Amitriptyline · Brotizolam · Butabarbital · Cinolazepam · Clotiazepam · Daridorexant +31 more
  8. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    This transformation mimics the final coagulation cascade step which involves the clotting mass that adheres to the wound surface and achieves hemostasis and sealing of open tissues. … Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting.

    Mixtures: EVICEL® SELLANTE DE FIBRINA HUMANA
  9. Target

    Neuronal acetylcholine receptor subunit alpha-7

    go.drugbank.com/bio_entities/BE0002341
    TargetHumans

    Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter … receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction.

    Synonyms: nAChR7
  10. Drug

    Elgemtumab

    go.drugbank.com/drugs/DB15430
    Investigational

    Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer